Edgar Filing: Corvese Brian - Form 4

Corvese Brian Form 4	1								
June 15, 2009	•								
FORM	4								PPROVAL
	UNITED	STATES			AND EX 1, D.C. 20		E COMMISSION	N OMB Number:	3235-0287
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction See Instruction See Instruction Section 16 (a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940						Estimated burden hou response	Estimated average burden hours per response 0.5		
1(b).									
(Print or Type Ro	esponses)								
1. Name and Address of Reporting Person <u>*</u> Corvese Brian		Person *	2. Issuer Name and Ticker or Trading Symbol ANTIGENICS INC /DE/ [AGEN]			5. Relationship of Reporting Person(s) to Issuer			
(Last)	(First) (Middle)				[110211]	(Che	eck all applicabl	e)
C/O ANTIGENICS INC., 162 FIFTH AVENUE, SUITE 900			3. Date of Earliest Transaction(Month/Day/Year)06/11/2009			X_ Director 10% Owner Officer (give title Other (specify below) below)			
	(Street)		4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person			
NEW YORK	, NY 10010						Person	More than One R	eporting
(City)	(State)	(Zip)	Tab	le I - Non-	Derivative	Securities A	Acquired, Disposed	of, or Beneficia	lly Owned
	2. Transaction Date Month/Day/Year)	2A. Deem Execution any (Month/Da	Date, if	Code (Instr. 8)	4. Securit onAcquired Disposed (Instr. 3, 4 Amount	(A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Reminder: Repo	rt on a separate line	e for each cl	ass of sec	urities bene	ficially own	ned directly	or indirectly.		
					Perso inforn requir	ns who rest nation cont ed to resp lys a curre	spond to the colle tained in this form ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount o
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

Edgar Filing: Corvese Brian - Form 4

(Instr. 3)	Price of Derivative Security	(Month/Day/Ye	ar) (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	ſ			
			Code	V (A) (D)) Date Exercisable	Expiration Date	Title	Amount or Number of Share
Stock Option (right to buy)	\$ 2.14	06/11/2009	А	15,000	06/11/2010 <u>(1)</u>	06/11/2019	Common Stock	15,000

Reporting Owners

Reporting Owner Name / Address				
	Director	10% Owner	Officer	Other
Corvese Brian C/O ANTIGENICS INC. 162 FIFTH AVENUE, SUITE 900 NEW YORK, NY 10010	Х			
Signatures				
Christine M. Klaskin, by Power of Attorney		06/15/20	009	
**Signature of Reporting Person		Date		
Explanation of Resp	oneo	e •		

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Options vest in three equal annual installments beginning June 11, 2010.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.